The findings of a recent survey, published last month, shows that 83 percent of general physicians, nurses and allied health professionals would recommend the use of cannabis therapy to treat patients with severe refractory epilepsy. However, only 48 percent of epilepsy specialists and general neurologists responded in support of it’s use because there is not enough sufficient clinical evidence on the subject. The goal of the survey was to collect “opinions about the use of medical marijuana and cannabidiol (CBD) for people with epilepsy.”
The study reported that 7 out of 10 people surveyed agree that cannabis does possess sufficient safety and efficacy in therapeutic uses. The majority of all participants, 78 percent, agreed that there should be a regulated cannabidiol (CBD) treatment available for epileptic patients. Almost every respondent from the patient and public category, 98 percent, reportedly would recommend the use of cannabis therapy in the treatment of epilepsy.
The survey was conducted by Epilepsia, a journal belonging to the International League Against Epilepsy (ILAE) from May 20 to September 1, 2014. A total of 776 people completed the survey. North American patients made up 58 percent of those surveyed. Epilepsy specialists and neurologists from Europe and North America made up 22 percent of the survey sample.
Eight total questions made up the survey. Half of those asked if the respondent thinks that there is sufficient safety and efficacy data, whether or not he or she would recommend the use of medical marijuana to treat epilepsy, and if “pharmacologic grade CBD compounds” should be available. Four questions addressed personal information about the participants.
Many of the studies conducted on the use of cannabis therapy to treat epilepsy have reported successful findings, but much more research and clinical trials need to be completed on the matter before most medical specialists will feel comfortable recommending this form of treatment.
photo credit: mlmedstaffing